Short Interest in Advanced Health Intelligence Ltd. (NASDAQ:AHI) Declines By 16.7%

Advanced Health Intelligence Ltd. (NASDAQ:AHI – Get Rating) was the target of a significant decrease in short interest in February. As of February 28th, there was short interest totalling 82,400 shares, a decrease of 16.7% from the February 13th total of 98,900 shares. Based on an average daily trading volume, of 208,100 shares, the days-to-cover ratio is currently 0.4 days.

Institutional Trading of Advanced Health Intelligence

Institutional investors have recently modified their holdings of the company. Susquehanna International Group LLP purchased a new stake in Advanced Health Intelligence in the fourth quarter worth $58,000. OLD Mission Capital LLC purchased a new stake in shares of Advanced Health Intelligence in the 3rd quarter worth about $37,000. Jane Street Group LLC bought a new stake in shares of Advanced Health Intelligence during the 1st quarter valued at about $33,000. Finally, Renaissance Technologies LLC purchased a new position in shares of Advanced Health Intelligence during the first quarter valued at about $29,000. 1.15% of the stock is currently owned by hedge funds and other institutional investors.

Advanced Health Intelligence Stock Down 3.4 %

Shares of Advanced Health Intelligence stock opened at $0.40 on Monday. The company has a quick ratio of 3.40, a current ratio of 0.90 and a debt-to-equity ratio of 0.05. Advanced Health Intelligence has a one year low of $0.35 and a one year high of $2.08. The business’s 50 day simple moving average is $0.48 and its two-hundred day simple moving average is $0.53.

About Advanced Health Intelligence

(Get Rating)

Advanced Health Intelligence Ltd. operates as a mobile application and technology development company in Australia and internationally. It develops and patents BodyScan, a proprietary measurement/dimensioning technology that enables end-user to check and assess body dimensions using a smartphone. The company also provides FaceScan for measuring vital signs, and risks associated with cardiovascular disease, heart attack, and stroke; and DermaScan, a dermatological scanner.